YC 170

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341128

CAS#: 59946-73-5

Description: YC 170 is a biochemical.

Chemical Structure

img
YC 170
CAS# 59946-73-5
Instruction

Theoretical Analysis

MedKoo Cat#: 341128
Name: YC 170
CAS#: 59946-73-5
Chemical Formula: C28H26ClN3O3
Exact Mass: 487.17
Molecular Weight: 487.984
Elemental Analysis: C, 68.92; H, 5.37; Cl, 7.26; N, 8.61; O, 9.84

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: YC 170; YC-170; YC170

IUPAC/Chemical Name: 3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-2,6-dimethyl-5-((phenylamino)carbonyl)-, 2-(2-pyridinyl)ethyl ester

InChi Key: YGKDFWHVQNDMLG-UHFFFAOYSA-N

InChi Code: InChI=1S/C28H26ClN3O3/c1-18-24(27(33)32-21-11-4-3-5-12-21)26(22-13-6-7-14-23(22)29)25(19(2)31-18)28(34)35-17-15-20-10-8-9-16-30-20/h3-14,16,26,31H,15,17H2,1-2H3,(H,32,33)

SMILES Code: CC1=C(C(C(=C(N1)C)C(=O)OCCc2ccccn2)c3ccccc3Cl)C(=O)Nc4ccccc4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 487.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Takeda Y, Tohse N, Nakaya H, Kanno M. Voltage-dependence of Ca2+ agonist effect of YC-170 on cardiac L-type Ca2+ channels. Br J Pharmacol. 1995 Oct;116(3):2134-40. PubMed PMID: 8640356; PubMed Central PMCID: PMC1908931.

2: Ichida S, Wada T, Matsuda N, Nakazaki S. Effects of Ca channel agonists on 45Ca uptake differ depending on the state of NG108-15 cells. Jpn J Pharmacol. 1994 Mar;64(3):209-12. PubMed PMID: 8022122.

3: Yamamoto T, Tokoro T, Eto Y. The attenuated elevation of cytoplasmic calcium concentration following the uptake of low density lipoprotein in type C Niemann-Pick fibroblasts. Biochem Biophys Res Commun. 1994 Jan 28;198(2):438-44. PubMed PMID: 8297353.

4: Takeda Y. [Single channel analysis of Ca2+ channel-agonistic action of dihydropyridine derivatives: voltage-dependent effects of YC-170 and BAY K 8644]. Hokkaido Igaku Zasshi. 1993 Jul;68(4):557-69. Japanese. PubMed PMID: 7687975.

5: Yano S, Horiuchi H, Horie S, Aimi N, Sakai S, Watanabe K. Ca2+ channel blocking effects of hirsutine, an indole alkaloid from Uncaria genus, in the isolated rat aorta. Planta Med. 1991 Oct;57(5):403-5. PubMed PMID: 1798789.

6: Shibasaki K, Uchida W, Matsuda Y, Asano M. Calcium entry blocking, beta 1-adrenoceptor blocking and hypotensive effects of YM-16151-4. Arch Int Pharmacodyn Ther. 1991 Sep-Oct;313:140-50. PubMed PMID: 1687772.

7: Ichida S, Ariyoshi S, Fujisue T, Wada T, Akimoto T. Effects of calcium channel agonists (BAY K 8644, CGP28392 and YC-170) on 45Ca uptake by rat uterine segments. Jpn J Pharmacol. 1991 Aug;56(4):397-402. PubMed PMID: 1720823.

8: Ogawa N. Effect of nicardipine on the relationship of renal blood flow and of renal vascular resistance to perfusion pressure in dog kidney. J Pharm Pharmacol. 1990 Feb;42(2):138-40. PubMed PMID: 1972402.

9: Higashi H, Sugita S, Matsunari S, Nishi S. Calcium-dependent potentials with different sensitivities to calcium agonists and antagonists in guinea-pig hippocampal neurons. Neuroscience. 1990;34(1):35-47. PubMed PMID: 2325852.

10: Abadie E, Marre M, Race JM, Luis N, Passa P. Vascular and insulinotropic effects of YC 170, a calcium agonist, on isolated perfused rat pancreas. Diabete Metab. 1990 Jan-Feb;16(1):7-10. PubMed PMID: 2185058.

11: Suzuki-Nishimura T, Sano T, Uchida MK. Effects of benzodiazepines on serotonin release from rat mast cells. Eur J Pharmacol. 1989 Aug 11;167(1):75-85. PubMed PMID: 2550260.

12: Lapchak PA, Araujo DM, Collier B. Regulation of endogenous acetylcholine release from mammalian brain slices by opiate receptors: hippocampus, striatum and cerebral cortex of guinea-pig and rat. Neuroscience. 1989;31(2):313-25. PubMed PMID: 2552347.

13: Bechem M, Gross R, Hebisch S, Schramm M. Ca-agonists: a new class of inotropic drugs. Basic Res Cardiol. 1989;84 Suppl 1:105-16. PubMed PMID: 2479372.

14: Takenaka T, Inagaki O, Terai M, Asano M, Kubo K. New 1,4-dihydropyridines with vasoconstrictor action through activation of Ca++-channels. J Pharmacol Exp Ther. 1988 Feb;244(2):699-708. PubMed PMID: 2450201.

15: Kidooka M, Matsuda M, Handa J. Effect of calcium antagonist and agonist on free fatty acid liberation in the ischemic brain of rats. Surg Neurol. 1987 Jul;28(1):41-5. PubMed PMID: 2438789.

16: Nakaya H, Hattori Y, Tohse N, Kanno M. Voltage-dependent effects of YC-170, a dihydropyridine calcium channel modulator, in cardiovascular tissues. Naunyn Schmiedebergs Arch Pharmacol. 1986 Aug;333(4):421-30. PubMed PMID: 2430192.

17: Hattori Y, Nakaya H, Tohse N, Kanno M. Vascular and cardiac effects of a new dihydropyridine derivative, YC-170: a comparison with Bay K 8644. J Pharmacol Exp Ther. 1986 Aug;238(2):670-8. PubMed PMID: 2426442.

18: Schramm M, Towart R. Modulation of calcium channel function by drugs. Life Sci. 1985 Nov 18;37(20):1843-60. Review. PubMed PMID: 2414632.

19: Preuss KC, Gross GJ, Brooks HL, Warltier DC. Slow channel calcium activators, a new group of pharmacological agents. Life Sci. 1985 Oct 7;37(14):1271-8. Review. PubMed PMID: 2413326.

20: Rogg H, Criscione L, Truog A, Meier M. In vitro comparative studies of the calcium-entry activators YC-170, CGP 28392, and BAY K 8644. J Cardiovasc Pharmacol. 1985;7 Suppl 6:S31-7. PubMed PMID: 2414592.